Markets brace for a crucial week. Investors watch US-Iran peace talks closely. Crude oil price drops also impact sentiment. Foreign investo...

Companies are facing massive AI bills, with one firm reportedly spending $500 million in a month on Claude AI due to unchecked usage. Sever...

Global bond markets are experiencing a selloff. Investors are concerned about rising energy prices due to the Middle East conflict. This co...

Swiggy's stock dipped 7% after reporting a 45% rise in Q4 FY26 revenue to Rs 6,383 crore and a narrowed net loss. Analysts cited a slowdown...

Lime, the electric bike and scooter company, has filed for a U.S. initial public offering. The firm reported a significant increase in year...

China's artificial intelligence services are surging, with its models processing vast amounts of data. This growth highlights its expanding...

Axis Bank shares fell 3% despite analysts maintaining a positive outlook, with 94% recommending 'Buy'. The bank's loan growth was strong, b...

Indian stock markets experienced sharp losses for the third consecutive session, with Sensex and Nifty falling over 1% each. Escalating Ira...

Wipro reported a 1.6% decline in annual revenue in fiscal year 2026 in constant currency terms, in line with its larger rival, Tata Consult...

Indian banks are expected to report a steady profit rise in the January-March quarter, four brokers said, aided by credit growth and liquid...

India's Reserve Bank of India has intervened to support the rupee, forcing local banks to unwind bearish bets. This move, while strengtheni...

Reliance Industries SEZ refinery will not face new export taxes on diesel and aviation fuel. This exemption stems from judicial pronounceme...

Indian markets plunged Thursday as President Trump's threats of escalating strikes on Iran spooked investors. The Sensex dropped significan...

Wall Street indexes experienced volatility as investors weighed rising oil prices against hopes for a U.S.-Iran de-escalation. President Tr...

CLSA analysts Mahesh Nandurkar and Ashish Agrawal are among those employees who are making the switch.

Most of the exits have happened from research, while one is said to be from the sales trading team.

Indian pharma companies, who have built their revenues by selling generic drugs to developed markets, might have to shift their business st...